Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Koji Yada"'
Autor:
Yuji Kashiwakura, Nemekhbayar Baatartsogt, Shoji Yamazaki, Azusa Nagao, Kagehiro Amano, Nobuaki Suzuki, Tadashi Matsushita, Akihiro Sawada, Satoshi Higasa, Naoya Yamasaki, Teruhisa Fujii, Taemi Ogura, Hideyuki Takedani, Masashi Taki, Takeshi Matsumoto, Jun Yamanouchi, Michio Sakai, Masako Nishikawa, Yutaka Yatomi, Koji Yada, Keiji Nogami, Ryota Watano, Takafumi Hiramoto, Morisada Hayakawa, Nobuhiko Kamoshita, Akihiro Kume, Hiroaki Mizukami, Shizukiyo Ishikawa, Yoichi Sakata, Tsukasa Ohmori
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 27, Iss , Pp 404-414 (2022)
Adeno-associated virus (AAV) vectors are promising modalities of gene therapy to address unmet medical needs. However, anti-AAV neutralizing antibodies (NAbs) hamper the vector-mediated therapeutic effect. Therefore, NAb prevalence in the target popu
Externí odkaz:
https://doaj.org/article/b43dde9c693b47fc933baa57f7dd8461
Autor:
Shoko Furukawa, Midori Shima, Kenichi Ogiwara, Tomoko Matsumoto, Koji Yada, Masahiro Takeyama, Tomoko Onishi, Kana Sasai, Keiji Nogami
Publikováno v:
International Journal of Hematology. 115:163-172
Global coagulation potential was assessed in 59 patients with acquired hemophilia A (PwAHA) by clot waveform analysis (CWA) and/or thrombin and plasmin generation assay. Relationships between factor VIII activity (FVIII:C) and the parameters from CWA
Autor:
Shoko Furukawa, Kenichi Ogiwara, Koji Yada, Masahiro Takeyama, Tomomi Niino, Midori Shima, Nogami Keiji
Publikováno v:
Blood Coagulation & Fibrinolysis.
Autor:
Shoko Furukawa, Yuto Nakajima, Kenichi Ogiwara, Naruto Shimonishi, Koji Yada, Midori Shima, Keiji Nogami, Kuniyoshi Mizumachi, Mariko Noguchi-Sasaki, Masahiro Takeyama
Publikováno v:
Thrombosis and Haemostasis. 121:1289-1298
Introduction Emicizumab prophylaxis improves coagulation function in congenital hemophilia A, regardless of inhibitor presence. We recently reported that emicizumab enhanced the coagulant potentials, ex vivo, in plasmas from patients with acquired he
Autor:
Keiji, Nogami, Masashi, Taki, Tadashi, Matsushita, Tetsuhito, Kojima, Toshiaki, Oka, Shouichi, Ohga, Kiyoshi, Kawakami, Michio, Sakai, Takashi, Suzuki, Satoshi, Higasa, Yasuo, Horikoshi, Keiko, Shinozawa, Shogo, Tamura, Koji, Yada, Masue, Imaizumi, Yoshitoshi, Ohtsuka, Fuminori, Iwasaki, Masao, Kobayashi, Junki, Takamatsu, Hideyuki, Takedani, Hisaya, Nakadate, Yoko, Matsuo, Takeshi, Matsumoto, Teruhisa, Fujii, Katsuyuki, Fukutake, Akira, Shirahata, Akira, Yoshioka, Midori, Shima
Publikováno v:
Haemophilia : the official journal of the World Federation of HemophiliaREFERENCES. 28(5)
Inhibitor-development is a serious complication in patients with haemophilia (PwH). Previous studies reported that therapeutic and genetic factors could be associated with these alloantibodies. Relevant clinical features such as genetic-background an
Autor:
Yuto Nakajima, Midori Shima, Kenichi Ogiwara, Naruto Shimonishi, Keiji Nogami, Shoko Furukawa, Koji Yada, Takeshi Kawamura, Masahiro Takeyama
Publikováno v:
International Journal of Hematology. 111:369-377
Type 2N von Willebrand disease (VWD) is characterized by impaired factor VIII (FVIII) binding to von Willebrand factor (VWF). Type 2N VWD patients generally exhibit mild bleeding tendency, but some exhibit a more severe hemorrhagic pattern. An assay
Autor:
Yuto Nakajima, Kuniyoshi Mizumachi, Naruto Shimonishi, Shoko Furukawa, Koji Yada, Kenichi Ogiwara, Masahiro Takeyama, Midori Shima, Keiji Nogami
Publikováno v:
International journal of hematology. 115(4)
Emicizumab reduces bleeding events in patients with severe hemophilia A (HA). The coagulation potential of emicizumab at a clinical dose appears to correspond to about 15 IU/dL of factor VIII activity (FVIII:C), the equivalent of converting from a se
Autor:
Koji, Yada
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 62(7)
The development of an inhibitor is a serious complication for patients with hemophilia (PwH). Previous international studies have reported some therapeutic and genetic factors associated with inhibitor development. However, actual situations, such as
Autor:
Koji Yada, Keiji Nogami
Publikováno v:
Journal of Blood Medicine. 10:171-181
Emicizumab is a factor (F)VIIIa-mimicking bispecific antibody recognizing FIXa and FX molecules. In the phase 1/2 clinical studies, once-weekly subcutaneous administration of emicizumab has shown a favorable safety profile with encouraging efficacy i
Autor:
Masahiro Takeyama, Kenichi Ogiwara, Shoko Furukawa, Yasuaki Shida, Keiji Nogami, Ryu Kasai, Hiroaki Yaoi, Midori Shima, Koji Yada
Publikováno v:
International Journal of Hematology. 110:419-430
Emicizumab is a bispecific antibody to factor (F) IX/IXa and FX/FXa, which mimics FVIIIa cofactor function. Emicizumab prophylaxis significantly decreases bleeding events for patients with hemophilia A (PwHA). However, global hemostatic monitoring in